Project Grant HT94252410968
Award Date
10/1/24
Completion Date
9/30/27
Dollars Obligated
$644K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This $172,374 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by Brigham & Women's Hospital, Inc. (a subsidiary of Partners Healthcare System) to investigate the role of fatty acid metabolism in chromophobe renal cell carcinoma. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing understanding of this type of kidney cancer. The...
The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $660,937 project grant to Brigham & Women's Hospital Inc. on September 30, 2023, to support the "Identification of Novel Therapeutic Strategies for Chromophobe RCC" research project. This 3-year grant will fund basic and applied biomedical research to investigate new treatment approaches for chromophobe renal cell carcinoma, a rare form of kidney cancer. Brigham & Women's...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
This $178,999 federal Project Grant, awarded on May 15, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Brigham & Women's Hospital Inc. to target TFE3 fusion proteins using PROTAC (Proteolysis Targeting Chimera) in translocation renal cell carcinoma (TRCC). The research aims to transform healthcare for military service members, veterans, and the broader public by developing innovative medical solutions. Brigham...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The Department of Defense's Defense Health Agency awarded a $1,428,720 Project Grant to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to investigate the use of menin/KMT2A protein degradation for the treatment of myeloid neoplasms. This research, conducted under the Military Medical Research and Development (CFDA 12.420) program, aims to transform healthcare for military service members, veterans, and the broader public through advanced biomedical research. The...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
Brigham & Women's Hospital Inc. was awarded a $1,523,784 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program to investigate cytoplasmic DNA-sensing pathways in BRCA1-deficient breast cancer development. The three-year award beginning July 1, 2022 will support research into medical solutions for breast cancer at the cellular level through studying the role of cytoplasmic DNA sensors in breast cancer tumor growth associated with...
The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $130,698 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support the development of the first targeted therapy for translocation renal cell carcinoma from August 15, 2022 to August 14, 2023. As the parent organization of the awardee, Partners Healthcare System Incorporated will oversee delivery of this innovative medical research effort to develop new...